Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
Phase 2 data on Spyre’s anti-TL1A antibody fell short of expectations, prompting the biotech to deprioritize monotherapy work in the indication.
Nick Paul Taylor
Aug 26, 2026 5:40am
J&J pays Sail $785M, securing option on in vivo CAR-T buyout
Jul 30, 2026 5:30am
Jasper merges with Kira, while Tavneos rival sent to Mirador
Jul 17, 2026 9:54am
Racing Takeda, InnoCare reports TYK2 inhibitor win in vitiligo
Jul 16, 2026 9:36am
Spero pivots to I&I via $1.1B deal with Innovent antibody
Jul 14, 2026 6:00am
Avere goes public via reverse merger, pays $120M for Hansoh drug
Jul 14, 2026 6:00am
